Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects....
In the latest trading session, McKesson (MCK) closed at $599.56, marking a -0.8% move from the previous day....
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2025 financial results after market close on Wednesday, August 7, 2024. The company will host a l...
NEW ORLEANS--(BUSINESS WIRE)--Outcomes, a leader in integrated pharmacy workflow and patient engagement solutions, announced that it will feature a new prescription counting solution, Pill Count, at M...
The healthcare sector is often considered a defensive play, with healthcare stocks to buy offering stability and growth potential even during economic downturns. The sector's strength is driven by an ...
Investors are optimistic about McKesson's (MCK) strength in its Biologics business....
In the most recent trading session, McKesson (MCK) closed at $603.24, indicating a +0.05% shift from the previous trading day....
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer....
